Hepatitis Monthly

Published by: Kowsar

Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis

Yihu Zheng 1 , Shengchu Zhang 1 , 2 , Hooi Min Tan Grahn 3 , Chao Ye 4 , Zheng Gong 2 and Qiyu Zhang 1 , *
Authors Information
1 Department of General Surgery, The First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang, China
2 Department of General Surgery, Yichang Central People’s Hospital, The First Clinical Medical College of Three Gorges University, Yichang, China
3 Metabolism, Obesity/Diabetes, Department of Biochemistry, Boston University School of Medicine, Boston, USA
4 State Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, Zhejiang University, Hangzhou, China
Article information
  • Hepatitis Monthly: June 01, 2013, 13 (4); e6496
  • Published Online: June 1, 2013
  • Article Type: Review Article
  • Received: September 13, 2012
  • Revised: November 10, 2012
  • Accepted: December 31, 2012
  • DOI: 10.5812/hepatmon.6496

To Cite: Zheng Y, Zhang S, Tan Grahn H M, Ye C, Gong Z, et al. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis, Hepat Mon. 2013 ; 13(4):e6496. doi: 10.5812/hepatmon.6496.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Galbraith RM, Williams R, Eddleston ALWF, Zuckerman AJ, Bagshawe KD. fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975; 306(7934): 528-30[DOI]
  • 2. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68(1): 105-12[PubMed]
  • 3. Bird GL, Smith H, Portmann B, Alexander GJ, Williams R. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med. 1989; 73(270): 895-902[PubMed]
  • 4. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990; 8(5): 261-70[PubMed]
  • 5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1): 182-8[PubMed]
  • 6. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer. 1992; 28(8–9): 1338-9[DOI]
  • 7. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med. 1985; 145(7): 1313-4[PubMed]
  • 8. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991. Cancer. 1996; 78(10): 2210-5
  • 9. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999; 81(1): 69-74[DOI][PubMed]
  • 10. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62(3): 299-307
  • 11. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol. 2005; 28(4): 379-84[PubMed]
  • 12. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004; 24(6): 540-6[DOI][PubMed]
  • 13. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003; 70(4): 553-61[DOI][PubMed]
  • 14. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010; 25(5): 864-71[DOI][PubMed]
  • 15. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125(6): 1742-9[PubMed]
  • 16. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma. 2003; 44(5): 759-66[DOI][PubMed]
  • 17. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22(5): 927-34[DOI][PubMed]
  • 18. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002; 99(2): 724-5[PubMed]
  • 19. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100(2): 391-6[PubMed]
  • 20. Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol. 2000; 108(2): 394-6[PubMed]
  • 21. Dai MS, Chao TY. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Breast Cancer Res Treat. 2005; 92(1): 95-6[DOI][PubMed]
  • 22. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148(7): 519-28[PubMed]
  • 23. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3): 209-15[DOI][PubMed]
  • 24. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006; 24(7): 1003-16[DOI][PubMed]
  • 25. Long M, Jia W, Li S, Jin L, Wu J, Rao N, et al. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat. 2011; 127(3): 705-12[DOI][PubMed]
  • 26. Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011; 104(4): 559-63[DOI][PubMed]
  • 27. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47(3): 844-53[DOI][PubMed]
  • 28. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006; 106(6): 1320-5[DOI][PubMed]
  • 29. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol. 2001; 65(3): 473-7[PubMed]
  • 30. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2): 209-20[DOI][PubMed]
  • 31. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997; 113(4): 1258-63[PubMed]
  • 32. Kao JH, Chen PJ, Lai MY, Chen DS. hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000; 118(3): 554-9
  • 33. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002; 99(7): 2324-30[PubMed]
  • 34. Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. J Biomed Sci. 2002; 9(2): 166-70[PubMed]
  • 35. Nishizono A, Kohno K, Takita-Sonoda Y, Hiraga M, Terao H, Fujioka T, et al. Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation. J Med Virol. 1997; 53(3): 266-72
  • 36. Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role. J Med Virol. 2000; 60(3): 249-55
  • 37. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004; 15(11): 1661-6[DOI][PubMed]
  • 38. Yoshiba M, Sekiyama K, Sugata F, Okamoto H, Yamamoto K, Yotsumoto S. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci. 1992; 37(8): 1253-9[PubMed]
  • 39. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7): 1306-11[DOI][PubMed]
  • 40. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1): 65-73[DOI][PubMed]
  • 41. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3): 678-86[DOI][PubMed]
  • 42. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000; 32(4 Pt 1): 828-34[DOI][PubMed]
  • 43. Okita R, Takahashi M, Narahara H, Sanada Y, Okada M, Kawakami Y, et al. Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. Clin J Gastroenterol. 2009; 2(3): 214-7[DOI]
  • 44. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996; 24(3): 711-3[DOI][PubMed]
  • 45. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001; 12 Suppl 1: 67-71[PubMed]
  • 46. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002; 17 Suppl 3-7[PubMed]
  • 47. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998; 27(6): 1670-7[DOI][PubMed]
  • 48. Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat. 1999; 6(5): 387-95[PubMed]
  • 49. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39(3): 857-61[DOI][PubMed]
  • 50. Coiffier B. Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. Cancer Invest. 2006; 24(5): 548-52[DOI][PubMed]
  • 51. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 52. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001; 34(3): 578-82[DOI][PubMed]
  • 53. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs. 2000; 60(4): 701-10[PubMed]
  • 54. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006; 4(9): 1076-81[DOI][PubMed]
  • 55. Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, et al. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy]. Rinsho Ketsueki. 2009; 50(12): 1715-9[PubMed]
  • 56. Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol. 2006; 41(2): 245-6[DOI][PubMed]
  • 57. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83(12): 769-74[DOI][PubMed]
  • 58. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005; 54(11): 1597-603[DOI][PubMed]
  • 59. Idilman R. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy. Gut. 2006; 55(8): 1208-9[PubMed]
  • 60. Zhang HY, Liu ZG, Zhang Z, Gong HY. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy]. Zhonghua Zhong Liu Za Zhi. 2010; 32(6): 459-62[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments